Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections

Expert Review of Anti-Infective Therapy

Volumn 15, Issue 1, 2017, Pages 55-65

  Bassetti, Matteo ^a   Carnelutti, Alessia ^a   Peghin, Maddalena ^a  

^a Servicio de Urologia   (Italy)

Author keywords

A.baumanii; carbapenemase; CRE; ESBL; Gram negative pathogens; Multi drug resistant; P.aeruginosa

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE;

ACINETOBACTER BAUMANNII; ALGORITHM; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; DRUG CHOICE; EPIDEMIOLOGICAL DATA; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; RISK ASSESSMENT; RISK FACTOR; COMBINATION DRUG THERAPY; DRUG EFFECTS; ENTEROBACTERIACEAE; ENZYMOLOGY; GRAM-NEGATIVE BACTERIAL INFECTIONS; METABOLISM; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT;

EID: 85003571579     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2017.1251840     Document Type: Review

References (86)

1. Zilberberg MD, Shorr AF, Micek ST, et al. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock:a retrospective cohort study. Crit Care. 2014;18(6):596. PubMed PMID:25412897. Pubmed Central PMCID:4264255.
2. Bassetti M, De Waele JJ, Eggimann P, et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 2015 May;41(5):776–795. PubMed PMID:25792203.• Comprehensive review on preventive and therapeutic options for critically ill patients with multidrug-resistant bacteria.
3. Hendrik TC, Voor in ‘T Holt AF, Vos MC., Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella spp.:a systematic review and meta-analyses. Plos One. 2015;10(10):e0140754. PubMed PMID:26485570. Pubmed Central PMCID:4617432.
4. Antunes NT, Lamoureaux TL, Toth M, et al. Class D beta-lactamases:are they all carbapenemases? Antimicrob Agents Chemother. 2014;58(4):2119–2125. PubMed PMID:24468778. Pubmed Central PMCID:4023754.
5. Quinn JP. Carbapenemases:a worldwide threat. Expert Rev Anti Infect Ther. 2013 Jul;11(7):643–644. PubMed PMID:23879603.
6. Philippon A, Slama P, Deny P, et al. A structure-based classification of class a beta-lactamases, a broadly diverse family of enzymes. Clin Microbiol Rev. 2016 Jan;29(1):29–57. PubMed PMID:26511485. Pubmed Central PMCID:4771212.
7. Borges-Walmsley MI, McKeegan KS, Walmsley AR. Structure and function of efflux pumps that confer resistance to drugs. Biochem J. 2003 Dec 1;376(Pt 2):313–338. PubMed PMID:13678421. Pubmed Central PMCID:1223791.
8. Huang Y, Yu X, Xie M, et al. Widespread dissemination of carbapenem-resistant Escherichia coli sequence type 167 strains harboring blaNDM-5 in clinical settings in China. Antimicrob Agents Chemother. 2016 Jul;60(7):4364–4368. PubMed PMID:27114282. Pubmed Central PMCID:4914679.
9. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. Jama. 2009 Dec 2;302(21):2323–2329. PubMed PMID:19952319.
10. Tabah A, Koulenti D, Laupland K, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units:the EUROBACT International Cohort Study. Intensive Care Med. 2012 Dec;38(12):1930–1945. PubMed PMID:23011531.
11. Martin-Loeches I, Torres A, Rinaudo M, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect. 2015 Mar;70(3):213–222. PubMed PMID:25445887.
12. Gudiol C, Royo-Cebrecos C, Laporte J, et al. Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients. Respirology. 2016 Jul 14;21:1411–1418. PubMed PMID:27417156.
13. Baker TM, Satlin MJ. The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies. Leuk Lymphoma. 2016 Oct;57(10):2245–2258. PubMed PMID:27339405.
14. Lim CJ, Cheng AC, Kennon J, et al. Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities:a nested case-control study. J Antimicrob Chemother. 2014 Jul;69(7):1972–1980. PubMed PMID:24710025.
15. Venkatachalam I, Yang HL, Fisher D, et al. Multidrug-resistant Gram-negative bloodstream infections among residents of long-term care facilities. Infect Control Hosp Epidemiol. 2014 May;35(5):519–526. PubMed PMID:24709720.
16. Dortet L, Cuzon G, Nordmann P. Dissemination of carbapenemase-producing Enterobacteriaceae in France, 2012. J Antimicrob Chemother. 2014 Mar;69(3):623–627. PubMed PMID:24275115.
17. Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission:derivation and validation of a scoring system. Antimicrob Agents Chemother. 2011 Jul;55(7):3485–3490. PubMed PMID:21537020. Pubmed Central PMCID:3122446.
18. Johnson SW, Anderson DJ, May DB, et al. Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum beta-lactamase-producing enterobacteriaceae on hospital admission. Infect Control Hosp Epidemiol. 2013 Apr;34(4):385–392. PubMed PMID:23466912. Pubmed Central PMCID:3641565.
19. Rodriguez-Bano J, Cisneros JM, Cobos-Trigueros N, et al. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enferm Infecc Microbiol Clin. 2015 May;33(5):337 e1–337 e21. PubMed PMID:25600218.
20. Ben-Ami R, Schwaber MJ, Navon-Venezia S, et al. Influx of extended-spectrum beta-lactamase-producing Enterobacteriaceae into the hospital. Clinl Infect Dis. 2006 Apr 1;42(7):925–934. PubMed PMID:16511754.
21. Kantele A, Laaveri T, Mero S, et al. Antimicrobials increase travelers’ risk of colonization by extended-spectrum betalactamase-producing Enterobacteriaceae. Clinl Infect Dis. 2015 Mar 15;60(6):837–846. PubMed PMID:25613287. Pubmed Central PMCID:4345818.
22. Poulakou G, Bassetti M, Timsit JF. Critically ill migrants with infection:diagnostic considerations for intensive care physicians in Europe. Intensive Care Med. 2016 Feb;42(2):245–248. PubMed PMID:26467709.
23. Reinheimer C, Kempf VA, Gottig S, et al. Multidrug-resistant organisms detected in refugee patients admitted to a University Hospital, Germany June–December 2015. Reinheimer C, Kempf VA, Göttig S, Hogardt M, Wichelhaus TA, O’Rourke F, Brandt C. Euro Surveill. 2016;21(2). doi:10.2807/1560-7917.ES.2016.21.2.30110. Pubmed PMID:26794850.
24. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia:implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med. 2004 Jan 6;140(1):26–32. PubMed PMID:14706969.
25. Rodriguez-Bano J, Navarro MD, Romero L, et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization:implications for control. Clinl Infect Dis. 2006 Jan 1;42(1):37–45. PubMed PMID:16323089.
26. Kengkla K, Charoensuk N, Chaichana M, et al. Clinical risk scoring system for predicting extended-spectrum beta-lactamase-producing Escherichia coli infection in hospitalized patients. J Hosp Infect. 2016 May;93(1):49–56. PubMed PMID:26905665.
27. Goodman KE, Lessler J, Cosgrove SE, et al. A clinical decision tree to predict whether a bacteremic patient is infected with an extended-spectrum beta-lactamase-producing organism. Clinl Infect Dis. 2016 Oct 1;63(7):896–903. PubMed PMID:27358356. Pubmed Central PMCID:5019284.•• Complete flow chart for clinical decision for suspected ESBL infections.
28. Correa L, Martino MD, Siqueira I, et al. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis. 2013;13:80. PubMed PMID:23398691. Pubmed Central PMCID:3574843.
29. Orsi GB, Bencardino A, Vena A, et al. Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation:results of a double case-control study. Infection. 2013 Feb;41(1):61–67. PubMed PMID:23070604.
30. Sanchez-Romero I, Asensio A, Oteo J, et al. Nosocomial outbreak of VIM-1-producing Klebsiella pneumoniae isolates of multilocus sequence type 15:molecular basis, clinical risk factors, and outcome. Antimicrob Agents Chemother. 2012 Jan;56(1):420–427. PubMed PMID:22005997. Pubmed Central PMCID:3256054.
31. Tumbarello M, Trecarichi EM, Tumietto F, et al. Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2014 Jun;58(6):3514–3520. PubMed PMID:24733460. Pubmed Central PMCID:4068482.
32. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK:a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010 Sep;10(9):597–602. PubMed PMID:20705517. Pubmed Central PMCID:2933358.
33. van der Bij AK, Pitout JD. The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae. J Antimicrob Chemother. 2012 Sep;67(9):2090–2100. PubMed PMID:22678728.
34. Miller BM, Johnson SW. Demographic and infection characteristics of patients with carbapenem-resistant Enterobacteriaceae in a community hospital:development of a bedside clinical score for risk assessment. Am J Infect Control. 2016 Feb;44(2):134–137. PubMed PMID:26492818.
35. Mortensen E, Trivedi KK, Rosenberg J, et al. Multidrug-resistant Acinetobacter baumannii infection, colonization, and transmission related to a long-term care facility providing subacute care. Infect Control Hosp Epidemiol. 2014 Apr;35(4):406–411. PubMed PMID:24602946.
36. Tacconelli E, Cataldo MA, De Pascale G, et al. Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex. J Antimicrob Chemother. 2008 Nov;62(5):1130–1137. PubMed PMID:18635519.
37. Dizbay M, Tunccan OG, Sezer BE, et al. Nosocomial imipenem-resistant Acinetobacter baumannii infections:epidemiology and risk factors. Scand J Infect Dis. 2010 Oct;42(10):741–746. PubMed PMID:20500117.
38. Vitkauskiene A, Dambrauskiene A, Cerniauskiene K, et al. Risk factors and outcomes in patients with carbapenem-resistant Acinetobacter infection. Scand J Infect Dis. 2013 Mar;45(3):213–218. PubMed PMID:23113773.
39. Sheng WH, Liao CH, Lauderdale TL, et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis. 2010 Sep;14(9):e764–e769. PubMed PMID:20646946.
40. Lee HY, Chen CL, Wu SR, et al. Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med. 2014 May;42(5):1081–1088. PubMed PMID:24394630.
41. Corbella X, Montero A, Pujol M, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol. 2000 Nov;38(11):4086–4095. PubMed PMID:11060073. Pubmed Central PMCID:87546.
42. Garnacho-Montero J, Dimopoulos G, Poulakou G, et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med. 2015 Dec;41(12):2057–2075. PubMed PMID:26438224.•• Specific recommendations about prevention and management of A. baumannii infections in the ICU elaborated by this multidisciplinary panel.
43. Cilloniz C, Gabarrus A, Ferrer M, et al. Community-acquired pneumonia due to multidrug and non-multidrug resistant Pseudomonas aeruginosa. Chest. 2016 Apr 6;150:415–425. PubMed PMID:27060725.
44. Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrug-resistant Pseudomonas aeruginosa:risk factors and clinical impact. Antimicrob Agents Chemother. 2006 Jan;50(1):43–48. PubMed PMID:16377665. Pubmed Central PMCID:1346794.
45. Micek ST, Wunderink RG, Kollef MH, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia:impact of multidrug resistance. Crit Care. 2015;19:219. PubMed PMID:25944081. Pubmed Central PMCID:4446947.
46. Tumbarello M, Repetto E, Trecarichi EM, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections:risk factors and mortality. Epidemiol Infect. 2011 Nov;139(11):1740–1749. PubMed PMID:21226988.
47. Nakamura A, Miyake K, Misawa S, et al. Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa. J Hosp Infect. 2013 Feb;83(2):153–155. PubMed PMID:23201400.
48. Gomez-Zorrilla S, Camoez M, Tubau F, et al. Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Antimicrob Agents Chemother. 2014 Oct;58(10):5863–5870. PubMed PMID:25049255. Pubmed Central PMCID:4187938.
49. Vestergaard M, Paulander W, Marvig RL, et al. Antibiotic combination therapy can select for broad-spectrum multidrug resistance in Pseudomonas aeruginosa. Int J Antimicrob Agents. 2016 Jan;47(1):48–55. PubMed PMID:26597931.
50. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009 Nov;136(5):1237–1248. PubMed PMID:19696123.
51. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs:no ESKAPE! An update from the Infectious Diseases Society of America. Clinl Infect Dis. 2009 Jan 1;48(1):1–12. PubMed PMID:19035777.
52. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae:differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015 Jul;70(7):2133–2143. PubMed PMID:25900159.•• The largest series of patients with CRE infections, which observed the superiority of combination therapy versus monotherapy using a propensity score model and the benefit of carbapenem including regimen (only for isolate with a carbapenem MIC ≤8 mg/L)
53. Morata L, Cobos-Trigueros N, Martinez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2012 Sep;56(9):4833–4837. PubMed PMID:22751533. Pubmed Central PMCID:3421866.
54. Zilberberg MD, Nathanson BH, Sulham K, et al. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis. Crit Care. 2016;20(1):221. PubMed PMID:27417949. Pubmed Central PMCID:4946176.
55. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev. 2012Jul;25(3):450–470. PubMed PMID:22763634. Pubmed Central PMCID:3416487.•• A comprehensive review on the debate regarding the use of combination versus monotherapy in patients infected with Gram-negative bacteria.
56. Pai MP, Cojutti P, Pea F. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function:a step toward dose optimization for the treatment of severe Gram-negative bacterial infections. Clin Pharmacokinet. 2015 Sep;54(9):933–941. PubMed PMID:25850987.
57. Bassetti M, Righi E, Carnelutti A. Bloodstream infections in the intensive care unit. Virulence. 2016 Apr 2;7(3):267–279. PubMed PMID:26760527. Pubmed Central PMCID:4871677.
58. Roberts JA, Paul SK, Akova M, et al. DALI:defining antibiotic levels in intensive care unit patients:are current beta-lactam antibiotic doses sufficient for critically ill patients? Clinl Infect Dis. 2014 Apr;58(8):1072–1083. PubMed PMID:24429437.
59. Harris PN, Tambyah PA, Paterson DL. Beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae:time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015 Apr;15(4):475–485. PubMed PMID:25716293.
60. Gutierrez-Gutierrez B, Bonomo RA, Carmeli Y, et al. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae:a multinational pre-registered cohort study. J Antimicrob Chemother. 2016 Jun;71(6):1672–1680. PubMed PMID:26907184. Pubmed Central PMCID:4867097.• A multinational retrospective cohort study on the efficacy of ertapenem for empirical and targeted therapy of bloodstream infections due to ESBL-E.
61. Gutierrez-Gutierrez B, Perez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of beta-lactam/beta-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016 Jul;60(7):4159–4169. PubMed PMID:27139473.
62. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae:importance of combination therapy. Clinl Infect Dis. 2012 Oct;55(7):943–950. PubMed PMID:22752516.
63. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections:lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–2328. PubMed PMID:24514083. Pubmed Central PMCID:4023796.
64. Rizek C, Ferraz JR, van der Heijden IM, et al. In vitro activity of potential old and new drugs against multidrug-resistant Gram-negatives. J Infect Chemothe. 2015 Feb;21(2):114–117. PubMed PMID:25456893.
65. Poulakou G, Bassetti M, Righi E, et al. Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. Future Microbiol. 2014;9(9):1053–1069. PubMed PMID:25340835.
66. Oliva A, Gizzi F, Mascellino MT, et al. Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae. Clin Microbiol Infect. 2016 Feb;22(2):147–153. PubMed PMID:26409059.
67. Bassetti M, Righi E, Esposito S, et al. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol. 2008 Dec;3(6):649–660. PubMed PMID:19072182.
68. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin:a comparison with imipenem-susceptible VAP. Clinl Infect Dis. 2003 May 1;36(9):1111–1118. PubMed PMID:12715304.
69. Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1311–1322. PubMed PMID:24532009.
70. Cheng A, Chuang YC, Sun HY, et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia:a multicenter prospective observational study. Crit Care Med. 2015 Jun;43(6):1194–1204. PubMed PMID:25793437.
71. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii:a multicenter, randomized clinical trial. Clinl Infect Dis. 2013 Aug;57(3):349–358. PubMed PMID:23616495.
72. Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection:importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005 Apr;49(4):1306–1311. PubMed PMID:15793102. Pubmed Central PMCID:1068618.
73. Pena C, Suarez C, Tubau F, et al. Carbapenem-resistant Pseudomonas aeruginosa:factors influencing multidrug-resistant acquisition in non-critically ill patients. Eur J Clin Microbiol Infect Dis. 2009 May;28(5):519–522. PubMed PMID:18949495.
74. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia:an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007 Aug;35(8):1888–1895. PubMed PMID:17581492.
75. Bassetti M, Luyt C-E, Nicolau DP, et al. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care. 2016 Dec;6(1):35. PubMed PMID:27090532. Pubmed Central PMCID:4835402.•• Complete review on aerosolized antibiotics.
76. Bassetti M, Welte T, Wunderink RG. Treatment of Gram-negative pneumonia in the critical care setting:is the beta-lactam antibiotic backbone broken beyond repair? Crit Care. 2016;20:19. PubMed PMID:26821535. Pubmed Central PMCID:4731981.
77. Sole-Lleonart C, Roberts JA, Chastre J, et al. Global survey on nebulization of antimicrobial agents in mechanically ventilated patients:a call for international guidelines. Clin Microbiol Infect. 2016 Apr;22(4):359–364. PubMed PMID:26723563.
78. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam:second-generation beta-lactam/beta-lactamase combinations. Clinl Infect Dis. 2016 Apr 20;63:234–241. PubMed PMID:27098166.• A comprehensive review on second-generation beta-Lactam/beta-lactamase combinations.
79. Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE):a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016 Jun;16(6):661–673. PubMed PMID:27107460.
80. Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2007 Mar;51(3):826–830. PubMed PMID:17145788. Pubmed Central PMCID:1803152.
81. De Rosa FG, Corcione S, Cavallo R, et al. Critical issues for Klebsiella pneumoniae KPC-carbapenemase producing K. pneumoniae infections:a critical agenda. Future Microbiol. 2015;10(2):283–294. PubMed PMID:25689539.
82. Viale P, Tumietto F, Giannella M, et al. Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clin Microbiol Infect. 2015 Mar;21(3):242–247. PubMed PMID:25658534.
83. Pelat C, Kardas-Sloma L, Birgand G, et al. Hand hygiene, cohorting, or antibiotic restriction to control outbreaks of multidrug-resistant Enterobacteriaceae. Infect Control Hosp Epidemiol. 2016 Mar;37(3):272–280. PubMed PMID:26708383.
84. Hayden MK, Lin MY, Lolans K, et al. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae in long-term acute-care hospitals. Clinl Infect Dis. 2015 Apr 15;60(8):1153–1161. PubMed PMID:25537877.
85. Otter JA, Yezli S, Schouten MA, et al. Hydrogen peroxide vapor decontamination of an intensive care unit to remove environmental reservoirs of multidrug-resistant Gram-negative rods during an outbreak. Am J Infect Control. 2010 Nov;38(9):754–756. PubMed PMID:20605263.
86. Bar-Yoseph H, Hussein K, Braun E, et al. Natural history and decolonization strategies for ESBL/carbapenem-resistant Enterobacteriaceae carriage:systematic review and meta-analysis. J Antimicrob Chemother. 2016 Jun 17;71:2729–2739. PubMed PMID:27317444.